VIRTRATE-K- potassium citrate and citric acid monohydrate liquid
Virtus Pharmaceuticals
----------
Prescription Systemic Alkalinizing Dietary Supplement1
Virtrate-K is an orally administered prescription systemic alkalinizing dietary supplement1 and should be administered under the supervision of a licensed medical practitioner.
Virtrate-K is an effective alkalinizing agent useful in those conditions in which long-term maintenance of an alkaline urine is desirable, such as in people with uric acid and cystine calculi of the urinary tract, and especially when the administration of sodium salts is undesirable or contraindicated. It is also effective potassium citrate may be preferable to sodium citrate.
Supplement Facts | |||
---|---|---|---|
Serving Size: 1 Teaspoon (5 mL) | |||
Amount Per Serving | % Daily Value for Children Under 4 Years of Age | % Daily Value for Adults and Children 4 or More Years of Age | |
Potassium Citrate Monohydrate | 1100 mg * | † | † |
Citric Acid Monohydrate | 334 mg * | † | † |
Other Ingredients: Propylene Glycol, Sorbitol, Polyethylene Glycol 400, Methylparaben, Propylparaben, Sucralose, FD&C Red #40, Natural Cherry Flavor and Purified Water.
Contains FD&C Red #40
Potassium citrate is absorbed and metabolized to potassium bicarbonate, thus it acts as a systemic alkalinizing agent.
Virtrate-K is highly concentrated, and when consumed after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock. When consumed as recommended, Virtrate-K alkalinizes the urine without producing a systemic alkalosis. It is highly palatable and pleasant tasting. Potassium citrate does not neutralize the gastric juice or disturb digestion.
Virtrate-K should be taken diluted in water according to directions, followed by additional water, if desired. Palatability is enhanced if chilled before taking.
3 to 6 teaspoonfuls (15 to 30 mL), diluted with 1 glass of water, after meals and at bedtime, or as directed by a physician.
1 to 3 teaspoonfuls (5 to 15 mL), diluted with 1/2 glass of water, after meals and at bedtime, or as directed by a physician.
2 to 3 teaspoonfuls (10 to 15 mL), diluted with a glassful of water, taken four times a day will usually maintain a urinary pH of 7.0-7.6 throughout most of the 24 hours without unpleasant side effects. To check urinary pH, HYDRION Paper (pH 6.0-8.0) or NITRAZINE Paper (pH 4.5-7.5) are available and easy to use.
Virtrate-K is contraindicated in people with severe renal impairment with oliguria or azotemia, untreated Addison's disease, adynamia episodica hereditaria, acute dehydration, heat cramps, anuria, severe myocardial damage, or hyperkalemia from any cause.
Large doses may cause hyperkalemia and alkalosis, especially in the presence of renal disease. Concurrent administration of potassium-containing medication, potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or cardiac glycosides may lead to toxicity.
Virtrate-K should be used with caution by people with low urinary output unless under the supervision of a physician. As with all liquids containing a high concentration of potassium, Virtrate-K should be diluted adequately with water to minimize the possibility of gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations; if possible, take each dose after meals to avoid saline laxative effect.
When consumed as recommended by people with normal renal function and urinary output, Virtrate-K generally has no unpleasant side effects. However, people with certain abnormal renal mechanisms should be careful to avoid development of hyperkalemia or alkalosis. Potassium intoxication causes listlessness, weakness, mental confusion, tingling of extremities, and other symptoms associated with a high concentration of potassium in the serum (hyperkalemia). Persons with renal disease should have periodic determinations of serum electrolytes in order to avoid the complications of hyperkalemia and alkalosis. These electrocardiographic abnormalities may also be observed with hyperkalemia: disappearance of the P wave, widening and slurring of QRS complex, changes of the S-T segment, tall peaked T waves.
The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, hyperkalemia can result (see Contraindications and Warnings). Hyperkalemia, when detected, must be treated immediately because lethal levels can be reached within a few hours.
Virtrate-K is supplied as red colored, cherry flavored liquid dispensed in 16 fl. oz. (472 mL) bottles.
VIRTUS
PHARMACEUTICALS
76439-262-16
VIRTRATE-K
Potassium Citrate and Citric Acid
Prescription Systemic Alkalinizing
Dietary Supplement*
Tamper evident by foil seal under cap.
Do not use if foil seal is broken or missing.
Rx
16 fl. oz. (473mL)
Sugar-Free
Made in the USA
VIRTRATE-K
potassium citrate and citric acid monohydrate liquid |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
Supplement Facts | ||
Serving Size : | Serving per Container : | |
Amount Per Serving | % Daily Value | |
---|---|---|
color | ||
flavor |
Labeler - Virtus Pharmaceuticals (969483143) |